Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition with Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods

Karen S. Pieper, Anastasios A. Tsiatis, Marie Davidian, Vic Hasselblad, Neal S. Kleiman, Eric Boersma, Wei Ching Chang, Jeffrey Griffin, Paul W. Armstrong, Robert M. Califf, Robert A. Harrington

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Background-Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. Methods and Results-We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. Conclusions-Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.

Original languageEnglish (US)
Pages (from-to)641-646
Number of pages6
JournalCirculation
Volume109
Issue number5
DOIs
StatePublished - Feb 10 2004

Keywords

  • Coronary disease
  • Glycoproteins
  • Trials

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition with Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods'. Together they form a unique fingerprint.

Cite this